Log In
Print
BCIQ
Print
Print this Print this
 

ixekizumab (LY2439821)

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionHumanized mAb against IL-17A
Molecular Target Interleukin-17A (IL-17A)
Mechanism of Action 
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today